Table 3. Association between serum IGF-1 level and initial stroke severity.
| Serum IGF-1 | OR [95% CI] | p |
|---|---|---|
| Model 1 | <0.001 | |
| Q1 | Reference | |
| Q2 | 0.78 [0.44-1.37] | 0.39 |
| Q3 | 0.37 [0.20-0.67] | <0.001 |
| Q4 | 0.45 [0.25-0.82] | 0.01 |
| Model 2 | 0.05 | |
| Q1 | Reference | |
| Q2 | 0.85 [0.48-1.50] | 0.57 |
| Q3 | 0.44 [0.24-0.82] | 0.01 |
| Q4 | 0.57 [0.30-1.09] | 0.09 |
| Model 3 | <0.001 | |
| Q1 | Reference | |
| Q2 | 0.94 [0.50-1.74] | 0.84 |
| Q3 | 0.39 [0.20-0.74] | <0.001 |
| Q4 | 0.44 [0.24-0.84] | <0.001 |
Model 1: crude OR; model 2: model 1 adjusted for age and sex; model 3: model 2 adjusted for body mass index, Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification, atrial fibrillation, smoking, white blood cell count, and high-sensitivity C-reactive protein.
CI: confidence interval, IGF-1: insulin-like growth factor-1, OR: odds ratio.